BioCentury
ARTICLE | Clinical News

N-3 polyunsaturated fatty acids: Phase III data

May 13, 2013 7:00 AM UTC

Researchers at the institute reported data from a double-blind, Italian Phase III trial in 12,513 patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who had not had a myocardial infarction (MI) showing that a once-daily 1 g dose of N-3 polyunsaturated fatty acids missed the primary endpoint of reducing the composite incidence of death from cardiovascular causes or hospital admission for cardiovascular causes at a median follow-up of 5 years vs. placebo (11.7% vs. 11.9%, p=0.58). Data were published in the New England Journal of Medicine. This is the first large-scale trial to evaluate fatty acids to lower cardiovascular risk. ...